These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23700288)

  • 1. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
    Gupta P; Mulkey F; Hasserjian RP; Sanford BL; Vij R; Hurd DD; Odenike OM; Bloomfield CD; Owzar K; Stone RM; Larson RA;
    Invest New Drugs; 2013 Oct; 31(5):1311-20. PubMed ID: 23700288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
    Brander D; Rizzieri D; Gockerman J; Diehl L; Shea TC; Decastro C; Moore JO; Beaven A
    Leuk Lymphoma; 2013 Dec; 54(12):2627-30. PubMed ID: 23488610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).
    Wang X; Owzar K; Gupta P; Larson RA; Mulkey F; Miller AA; Lewis LD; Hurd D; Vij R; Ratain MJ; Murry DJ;
    Br J Clin Pharmacol; 2014 Nov; 78(5):1005-13. PubMed ID: 24838014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
    Jahan T; Gu L; Kratzke R; Dudek A; Otterson GA; Wang X; Green M; Vokes EE; Kindler HL
    Lung Cancer; 2012 Jun; 76(3):393-6. PubMed ID: 22197613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
    Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG
    Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
    Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
    Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
    Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
    Joensuu H; De Braud F; Coco P; De Pas T; Putzu C; Spreafico C; Bono P; Bosselli S; Jalava T; Laurent D; Casali PG
    Ann Oncol; 2008 Jan; 19(1):173-7. PubMed ID: 17698976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
    Komrokji RS; Padron E; Yu D; Fulp WJ; Rodriguez Y; Tinsley S; List AF; Lancet JE
    Am J Hematol; 2014 Aug; 89(8):809-12. PubMed ID: 24764152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
    Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
    Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
    Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
    Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
    Gauler TC; Besse B; Mauguen A; Meric JB; Gounant V; Fischer B; Overbeck TR; Krissel H; Laurent D; Tiainen M; Commo F; Soria JC; Eberhardt WEE
    Ann Oncol; 2012 Mar; 23(3):678-687. PubMed ID: 21617019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
    Garcia-Manero G; Khoury HJ; Jabbour E; Lancet J; Winski SL; Cable L; Rush S; Maloney L; Hogeland G; Ptaszynski M; Calvo MC; Bohannan Z; List A; Kantarjian H; Komrokji R
    Clin Cancer Res; 2015 Mar; 21(5):985-94. PubMed ID: 25480830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Gatter KC; Trarbach T; Folprecht G; Shi MM; Lebwohl D; Jalava T; Laurent D; Meinhardt G; Harris AL;
    Br J Cancer; 2012 Sep; 107(7):1044-50. PubMed ID: 22910317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
    Gerstner ER; Eichler AF; Plotkin SR; Drappatz J; Doyle CL; Xu L; Duda DG; Wen PY; Jain RK; Batchelor TT
    J Neurooncol; 2011 Jun; 103(2):325-32. PubMed ID: 20821342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
    Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.